Dichotomous roles for the orphan nuclear receptor NURR1 in breast cancer by Shawn Llopis et al.
Llopis et al. BMC Cancer 2013, 13:139
http://www.biomedcentral.com/1471-2407/13/139RESEARCH ARTICLE Open AccessDichotomous roles for the orphan nuclear
receptor NURR1 in breast cancer
Shawn Llopis1, Brittany Singleton1, Tamika Duplessis2, Latonya Carrier2, Brian Rowan2 and Christopher Williams1*Abstract
Background: NR4A orphan nuclear receptors are involved in multiple biological processes which are important in
tumorigenesis such as cell proliferation, apoptosis, differentiation, and glucose utilization. The significance of NR4A
family member NURR1 (NR4A2) in breast cancer etiology has not been elucidated. The purpose of this study was to
ascertain the impact of NURR1 expression on breast transformation, tumor growth, and breast cancer patient
survival.
Methods: We determined the expression of NURR1 in normal breast versus breast carcinoma in tissue microarrays
(immunohistochemistry), tissue lysates (immunoblot), and at the mRNA level (publically available breast
microarrays). In addition NURR1 expression was compared among breast cancer patients in cohorts based on p53
expression, estrogen receptor α expression, tumor grade, and lymph node metastases. Kaplan-Meier survival plots
were used to determine the correlation between NURR1 expression and relapse free survival (RFS). Using
shRNA-mediated silencing, we determined the effect of NURR1 expression on tumor growth in mouse xenografts.
Results: Results from breast cancer tissue arrays demonstrate a higher NURR1 expression in the normal breast
epithelium compared to breast carcinoma cells (p ≤ 0.05). Among cases of breast cancer, NURR1 expression in the
primary tumors was inversely correlated with lymph node metastases (p≤ 0.05) and p53 expression (p ≤ 0.05).
Clinical stage and histological grade were not associated with variation in NURR1 expression. In gene microarrays,
4 of 5 datasets showed stronger mean expression of NURR1 in normal breast as compared to transformed breast.
Additionally, NURR1 expression was strongly correlated with increase relapse free survival (HR = 0.7) in a cohort of
all breast cancer patients, but showed no significant difference in survival when compared among patients whom
have not been treated systemically (HR = 0.91). Paradoxically, NURR1 silenced breast xenografts showed significantly
decreased growth in comparison to control, underscoring a biphasic role for NURR1 in breast cancer progression.
Conclusions: NURR1 function presents a dichotomy in breast cancer etiology, in which NURR1 expression is
associated with normal breast epithelial differentiation and efficacy of systemic cancer therapy, but silencing of
which attenuates tumor growth. This provides a strong rationale for the potential implementation of NURR1 as a
pharmacologic target and biomarker for therapeutic efficacy in breast cancer.
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The NR4A family (NR4A1, NR4A2, and NR4A3) is a
family of orphan nuclear receptors whose activity is
shown to promote cell proliferation, apoptosis, and ter-
minal differentiation in a tissue dependent manner [1].
All three family members have been shown to play roles
in hematopoietic differentiation, while NURR1 (NR4A2,
TINUR) activity is necessary for dopaminergic neuron
differentiation [2-5]. Structural studies suggest that
NR4As are “true orphan receptors”, in that the ligand
binding pocket is thought to be obstructed by hydropho-
bic amino acid side chains rendering it inaccessible to li-
gands [6]. Despite the lack of a physiological ligand,
NR4A receptors are targeted by several hormones and
xenobiotic compounds which induce NR4A gene expres-
sion and/or directly bind to and elicit NR4A transactiva-
tion function [7-11]. Functionally, NR4As mediate gene
expression by binding as monomers to NBRE [(NGFI-β
Nerve growth factor inducible β) Response Element], as
homodimers to NURRE (NUR-like Response Element),
or as heterodimers with retinoid X receptor to DR5 re-
sponse elements [12-15]. In addition to transactivation
functions, NR4As have been shown to translocate to
the mitochondria to induce apoptosis (NR4A1) and to
modulate the activity of other proteins through protein-
protein interactions (NURR1) [16-18].
Despite its role in differentiation, NURR1 has been
implicated in promotion of cancer cell proliferation.
Cytoplasmic localization of NURR1 is associated with
decreased patient survival in bladder cancer patients
while expression of NURR1 allowed HeLa retrovertant
cell lines to regain tumorigenicity [19,20]. Additionally,
prostaglandin-mediated cytoprotection has also been
shown to be dependent on NURR1 expression [21].
Similarly, thromboxane A mediated lung cancer cell
proliferation is in part mediated through NURR1 [22].
Conversely, drugs which transactivate NURR1 have been
shown to be associated with apoptosis. For instance,
NURR1 has been identified as a target of the anti-
neoplastic drug 6-mercaptopurine, and may contribute
to its anti-neoplastic functions, while 1, 1-bis(3′-
indolyl)-1-(p-chlorophenyl)methane (DIM-C-pPhCl), an
activator of NURR1 has been shown to mediate apop-
tosis in bladder cancer cells [10,23].
Despite these findings, the impact of NURR1 expres-
sion has yet to be elucidated in breast cancer. In order
to gain insight into the function of NURR1 in breast
cancer, we performed immunohistochemical staining for
NURR1 on breast tissue arrays and compared the ex-
pression of NURR1 protein in normal vs. transformed
breast tumor samples. Furthermore, we compared the
level of NURR1 expression among tumor samples strati-
fied according to lymph node status, histological grade,
estrogen receptor α (ERα) status, and p53 expressionstatus. To support these findings, we codified NURR1
expression in several publically available microarray
datasets in which normal breast epithelium was com-
pared to cancerous breast. Relapse free survival (RFS) of
patients exhibiting high or low NURR1 expression was
compared to determine the association of NURR1 with
breast cancer recurrence. Additionally, we developed a
xenograft model to determine the impact of NURR1 si-
lencing in breast tumor development. These studies sup-
port the contention that NURR1 could be an efficacious
target in cancer chemoprevention and therapy, as well as
a potential biomarker for treatment efficacy in breast
cancer.
Methods
Breast tissue microarrays and immunohistochemistry
Breast tumor microarrays (BR953) were purchased from
US Biomax incorporated for immunohistochemical
staining. Briefly, slides were deparaffininzed at 60°C and
incubated in xylenes for 3 minutes. Slides were subse-
quently rehydrated by incubation in graded ethanol at
100%, 90%, and 75%. Heat-induced epitope retrieval
(HIER) was performed in an autoclave at 100°C, for 10
minutes, at 15 PSI, in 20mM Tris, pH 8.5. Antibodies
used for immunohistochemical staining included nor-
mal rabbit IgG (negative control) or α-NURR1 (N-20,
Santa Cruz Biotechnology). Peroxide block, blocking,
antibody incubation, and secondary detection were
performed utilizing UltraVision One Polymer IHC de-
tection systems (Thermo Scientific) in accordance with
the manufacturer’s instruction. Stained core images
were captured using an Olympus BX51 and DP72 color
camera. Cores were each scored according to staining
intensity (0 = negative, 1 = marginal/weak, 2 = moderate,
3 = strong) twice each by 2 blind observers and the
mean scores recorded. Mean IHC scores of normal and
cancerous epithelium were compared using Mann-
Whitney U-test. For further analyses, biopsies with a
mean score of less than 1.5 were scored as NURR1(-),
and those at 1.5 or above were designated as NURR1(+).
Utilizing pathology reports, patient data was stratified
according to TP53 expression, ERα expression, lymph
node status, and histological grade. Statistical signifi-
cance was determined using Fisher’s exact test. Images
of histological (hematoxylin and eosin) stains for each
tumor core are available at http://www.biomax.us/tis-
sue-arrays/Breast/BR953.
Western immunoblot
For Western immunoblots, normal and cancerous tu-
mor lysates were purchased from Origene technologies.
Lysates from established cell lines (MDA-MB-468 and
MDA-MB-231) cell lines were generated from 60% con-
fluent 100 cm2 cell culture plates using 1% SDS buffer
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cocktail. All protein lysates were fractionated by poly-
acrylamide gel electrophoresis (PAGE) and transferred
to nitrocellulose. Nitrocellulose blots were blocked and
probed in the presence of 5% bovine serum albumin for
the presence of α-NURR1 and a β-actin antibodies. Sec-
ondary immunodetection was performed by incubation
with AlexaFluor-647 or AlexaFluor-488 secondary anti-
bodies, respectively. Immunofluorescence was detected
using the BioRad VersaDoc imaging system.
Tissue culture and cell line generation
MDA-MB-468 and MDA-MB-231 cells were acquired
from American Tissue Type Collection (ATCC) and uti-
lized to generate novel cell lines (4A2KD-468, 4A2KD-
231, Vec-468, and Vec-231). 4A2KD- and Vec- cells
lines were generated by stable transfection with plasmids
(pGFP-V-RS vector, Origene) expressing scrambled short
hairpin RNA (shRNA) or a shRNA targeting NURR1
(Vec- and 4A2KD- cells, respectively) using Fugene HD
(Roche) in accordance with the manufacturer’s proto-
cols. Stably transfected cells were selected by FACS
(fluorescence assisted cell sorting) gating according to
GFP fluorescence at 5 days post-transfection (Tulane
University Cell Analysis Core). All cell lines were cul-
tured in Dulbecco’s modified eagle’s media (DMEM),
supplemented with 10% fetal bovine serum and penicil-
lin/streptomycin, and maintained at 37°C and 5% CO2.
Tumor xenografts
Four- to five-week old female homozygous athymic nude
mice (Hsd-nude-Foxn1nu, approximately 20 grams each)
were purchased from Harlan Laboratories. After 10 days
quarantine, each mouse was identified by numbered ear
tags and randomly assigned to 4 cage groups with 6
mice each: Vec-468, 4A2KD-468, Vec-231, and 4A2KD-
231. The GFP-expressing cells were cultured to 80%
confluence in 150 mm2 tissue culture plates, then col-
lected and divided into aliquots containing 5×105 cells
with Matrigel suspension. Each mouse was inoculated
once by injection of cell/Matrigel suspension (200 μl)
into the inguinal mammary fat pad with 5×105 cells.
After day 10, tumors were imaged for GFP fluorescence
using the Maestro Flex small animal imager (day 0), and
then weekly for five weeks thereafter to measure tumor
progression as indicated by fluorescence intensity. Dur-
ing imaging, mice were anesthetized (intraperitoneal
injection with ketamine/xylazine) to immobilize the ani-
mals during image acquisition. Images were spectrally
unmixed and fluorescence totals reported. Upon termin-
ation of the study, mice were euthanized by exposure to
CO2 in a manner as to minimize animal distress. All ani-
mals were housed in the Animal Care Facility on-site
and received humane care according to the guidelines ofthe Institutional Animal Care and Use Committee
(IACUC) of Xavier University of Louisiana.
Data mining
GEO microarray array public repository was initially
searched for microarrays in which global gene expres-
sion in normal breast epithelium was compared to that
of cancerous breast tissue. Within the search, 5 studies
were identified. NURR1 expression values were derived
from each dataset, and relative expression of NURR1
was compared using Student’s T-test for significance,
where significance was determined as p ≤ 0.05.
Kaplan-Meier survival analysis was performed utilizing
kmplotter server (kmplot.com), which analyzes breast
cancer patient survival data from public microarray data
repositories. Patients were stratified as NURR1-low or
NURR1-high according to the median expression values
for NURR1 throughout the cohort (Affymatrix probe
216248_s). RFS in the total population (2898 patients)
was determined and compared to that of patients which
did not receive systemic therapy (845 patients).
Results
NURR1 is strongly expressed in normal, but not
cancerous breast tissue
NURR1 impacts proliferation and differentiation in a
context-dependent fashion. As such, we sought to com-
pare the expression of NURR1 in normal and cancerous
breast epithelium using tissue microarrays. Tissue
microarrays were stained with antibodies directed
against NURR1 or with normal IgG, and each tissue core
was scored according to the intensity of NURR1 staining
in epithelial cells (0 = absent and 3 = greatest intensity).
NURR1 was strongly expressed in normal breast epithe-
lium, with a mean intensity score of 2.4 (Figure 1A, B).
This differed significantly from cancerous tissue cores
which had a mean intensity score of 1.4 (Figure 1A, B).
This specific silencing of NURR1 in transformed breast
was confirmed in using Western immunoblots, where
relative NURR1 expression was determined in lysates
from normal breast epithelium, transformed breast, and
established cell lines (MDA-MB-468 and MDA-MB-
231). Loss of NURR1 expression is evident in cancerous
breast as compared to normal breast, (Figure 1C). These
findings support the contention that NURR1 expression
in the breast is commensurate with a normal, terminally
differentiated epithelial phenotype, whereas as silencing/
dysregulation of NURR1 may play a role in oncogenic
transformation of breast epithelial cells.
NURR1 expression is associated with specific prognostic
indices in breast cancer
Since NURR1 showed a highly significant decrease in ex-





































Figure 1 NURR1 is weakly expressed in cancerous breast epithelium, but strongly expressed in the normal breast epithelium. A)
Immunohistochemical staining of breast tissue microarrays reveals expression of NURR1 in tissue cores correlating to normal and malignant
breast. Images typical of scoring are depicted, with normal breast tissue shown in the lower panel. B) Each tissue core was scored independently
and the mean for normal and cancerous epithelium compared using Mann-Whitney U-Test, p = 0.0016. Hematoxylin and eosin staining of each
core is available at http://www.biomax.us/tissue-arrays/Breast/BR953 C) NURR1 expression was determined by Western immunoblot of protein
lysates derived from normal breast epithelium, cancerous breast epithelium, and established breast cancer cell lines (MDA-MB-468, MDA-MB-231).
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cific surrogate prognostic indices among breast cancer
patients. Breast tumors were categorized into groups
of either negative to marginally expressing NURR1
[NURR(-)] and those moderately to strongly expressing
NURR1 [NURR(+)], based on previously determined
mean IHC scores (0.0-1.49, 1.50-3.0, respectively).
Subsequently, each sample was categorized according
to accompanying pathology reports with regard to ERα
status, p53 status, presence of lymph node metastases
(from TNM classification), and histological grade.
NURR1 expression was strikingly lower among pri-
mary tumors of patients with lymph node metastases
(Figure 2A). Indeed each of the primary tumors associ-
ated with lymph nodes was NURR1(-) suggesting a
strong link between NURR1 silencing and cancer cell
invasiveness (Figure 2A). Additionally, we found that
NURR1 expression was inversely related to expression
of p53 (Figure 2B). Though the correlation was not of
statistical significance, NURR1(-) tumors tended to be
ERα(+) (Figure 2C). No differences were observed be-
tween the histological grades represented with regard
to NURR1 expression (Figure 2D).Data mining confirms NURR1 silencing in transformed
breast as compared to normal breast epithelia
To confirm that NURR1 expression is selectively silenced
in transformed breast cells, we analyzed published gene
expression microarrays in the Gene Expression Omnibus
(GEO) repository which entailed comparisons of normal
and transformed breast epithelium. We then compared
the expression of NURR1 between cancerous and normal
patient samples. Four of five studies revealed decreases in
mean NURR1 mRNA expression in transformed breast
cancer samples as compared to normal breast epithelium,
three of which reached statistical significance, p ≤0.05
(Table 1) [24-28]. This supports our own breast tissue
microarrays findings demonstrating that loss of NURR1
expression is indeed associated with oncogenic transform-
ation of the breast epithelium. Interestingly, those cohorts
showing the most significant difference appeared in stud-
ies in which normal tissue was derived from breast reduc-
tion mammoplasty where no diagnosis of breast cancer
had been made. Conversely, the 2 datasets (GDS2739 and
GDS2635) which showed no statistically significant differ-
ence in NURR1 expression, involved use of tumor-
adjacent normal breast tissue. As such, it is plausible that


































































Figure 2 NURR1 protein expression correlates with specific prognostic indicators in breast cancer biopsies. Breast tumor microarray cores
which were previously scored were categorized as either NURR1(-) (mean IHC score, < 1.5) or NURR1(+) (mean IHC score, ≥1.5). Subsequently,
each category was compared with regard to several clinicopathological features (lymph node status, p53 status, ERα expression) using Fisher’s
Exact Test. NURR1 is silenced in the primary tumors of patients with lymph node metastasis (A, p = 0.0292) and is inversely correlated to p53
expression (B, p = 0.0481). NURR1 status did not significantly correlate with ERα status (C, p = 0.1790) or histological grade (D, p = 0.928).
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breast epithelial cell transformation, but may be a marker
of pre-neoplastic breast epithelium.
NURR1 is associated with prolonged RFS in breast cancer
patients
Lymph node metastases and p53 expression serve as
surrogate markers for breast cancer prognosis, but may
not correlate directly with patient survival. As such, we
utilized the kmplot.com server to determine the rela-
tionship between NURR1 expression and RFS in breast
cancer patients [29]. Using the JETset best probe func-
tion, we identified Affymatrix probe 216248_s_at as the
most suitable probe for determination of NURR1 ex-
pression. Patients were designated as NURR-high or
NURR1-low based on the median expression of NURR1
within the complete cohort. Kaplan-Meier analysis of
2898 breast cancer patients reveal that NURR1 is signifi-
cantly associated with improved prognosis as determinedTable 1 NURR1 expression in gene expression microarrays co
GEO dataset Normal Cancer/Hyp
GDS3139 1942 ± 396.6 N=15 417.8 ± 35.81
GDS2739 1691 ± 943.0 N=8 487.2 ± 115.3
GDS3716 1718 ± 265.2 N=18 535.6 ± 108.7
GDS2635 327.3 ± 93.02 N=19 296.2 ± 59.50
GDS2250 7.780 ± 0.3715 N=7 6.290 ± 0.253by RFS, where HR = 0.7 (0.62-0.79, LogrankP = 2×10-8)
(Figure 3A). However, when limited to patients not re-
ceiving systemic therapy (846 patients), NURR1 failed
to reveal any RFS advantage [HR = 0.91 (0.72-1.14,
logrankP =0.40) (Figure 3B). This suggests that the posi-
tive prognostic significance of NURR1 may be less re-
lated to disease progression, but more indicative of the
efficacy of systemic therapy in prolonging time to
relapse.
NURR1 silencing inhibits breast tumor xenograft growth
In order to determine the impact of NURR1 silencing
on breast cancer cell proliferation, we stably transfected
MDA-MB-468 and MDA-MB-231 cells with a short
hairpin RNA (shRNA) encoding plasmids directed to-
ward either NURR1 or a scrambled hairpin RNA as a
control, (4A2KD- and Vec-, respectively), resulting in
suppression of NURR1 protein expression in 4A2KD-
468 and 4A2KD-231 cells. In addition, each plasmidmparing normal and cancerous breast epithelium
erplasia T-Test PMID
N=14 P = 0.0010 18058819
N=8 P = 0.2257 17591970
N=18 P = 0.0002 20197764
N=11 P = 0.8143 17389037
8 N=40 P = 0.0223 16473279,20400965
Figure 3 NURR1 expression is associated with increased relapse free survival (RFS). Survival of patients expressing above median NURR1
mRNA (NURR1high) was compared to patients with below median expression (NURR1low) levels of NURR1 mRNA. A) Among all patients, those
categorized as NURRhigh had a substantial RFS benefit as compared to NURR1low (HR = 0.7, N = 2989) B) The RFS benefit observed among
NURR1high patients was not apparent in patients which did not receive systemic therapy for the treatment of breast cancer (HR = .91, N = 845).
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efficient determination of stable transgene incor-
poration and monitoring of tumor growth. We sub-
sequently established orthotopic mouse tumors in
Hsd-Nude-foxn1nu athymic nude mice; after which the
tumors were allowed to progress for 35 days and the
tumor size was monitored by GFP fluorescence. A di-
vergence in tumor growth rate was observed by day 14
and by day 35, Vec-468 tumors had grown at a signifi-
cantly faster rate and were 60% larger than 4A2KD468-
tumors, Figure 4A, B). 4A2KD-231 cells were more
efficient in establishing tumors, and by day 35 showed a
substantial increase in growth as compared to Vec-231
derived tumors. Additionally, 4 of 6 mice inoculated
with Vec-231 cells developed detectable contralateral
mammary lesions whereas none were detected among
mice inoculated with 4A2KD-231 cells, highlighting a
potential role for NURR1 expression in breast cancer
cell invasion. When taken into consideration with previ-
ous findings, these data suggest a dichotomous role for
NURR1 in breast cancer development in which NURR1
is highly expressed in normal, non-proliferating breast
epithelium, but acquires proliferation promoting effects
in transformed tissue.
Discussion
Our studies suggest that NURR1 has profound, context
dependent effects on breast cancer and normal breast
epithelium with regard to tumorigenicity and terminal
differentiation, respectively. We have demonstrated that
NURR1 is strongly expressed in the normal breast epi-
thelium, but is suppressed in the transformed breast,
suggesting a potential role for NURR1 in the mainten-
ance of a differentiated epithelial phenotype. Our studies
also reveal that NURR1(-) primary tumors are more
likely to be associated with p53 expression as well asincreased incidence of lymph node metastases, when
compared to NURR1(+) tumors. Paradoxically, breast
cancer xenograft tumors in which NURR1 has been
targeted by stable transfection with shRNA reveal that
further loss of NURR1 leads to decreased tumor growth
as compared to control. These findings suggest a dichot-
omous role for NURR1 in breast cancer development
which may be substantially impacted by the cellular con-
text under which the receptor is expressed.
NURR1 in cancer
The contention that NURR1 plays an important role in
the maintenance of terminal differentiation of epithelia
is supported in the literature. Developmental animal
models have shown that suppression of NURR1 is neces-
sary for the maintenance of pluripotency of hemato-
poietic progenitor cells [3]. Similarly, genetic models
have demonstrated that the loss of NR4A-family recep-
tors results in increased incidence of leukemia [30].
NURR1 expression and activity is induced in response to
several compounds with anti-neoplastic effects such as 6
mercaptopurine and 1,1-bis(3′-indolyl)-1-(aromatic)me-
thane (C-DIM) analogs [7,10]. In contrast, several stud-
ies suggest that NURR1 is associated with increased
proliferation of cancer cells. In HeLa cells, loss of
NURR1 was associated with decreased anchorage inde-
pendent growth and resulted in apoptosis, suggesting
that NURR1 was necessary for the maintenance of a
tumorigenic phenotype [20]. In colon cancer, it has been
demonstrated that prostaglandin E2 mediated prolifera-
tion is inhibited by expression of a dominant negative
NURR1, demonstrating that NURR1 is indeed necessary
for eicosanoid-mediated proliferation in colon cancer
[21]. It is feasible that NURR1, which is highly regulated
at the transcriptional and post-translational levels, may
have different roles in cancer based on the regulatory



















































Figure 4 Silencing of NURR1 expression inhibits in growth of mammary xenograft tumors. A) Cell lines stably transfected with plasmids
expressing GFP with (4A2KD-) or without (Vec-) shRNA against NURR1 were generated from MDA-MB-468 and highly invasive MDA-MB-231 breast
cancer cell lines. NURR1 silencing efficiency was ascertained by Western blot. Athymic nude mice were inoculated by injection with 5×105, and
tumor growth was monitored over 35 days by GFP fluorescence using a Maestro Flex small animal imager (Vec-468 and 4A2KD-468 upper panels,
Vec-231 and 4A2KD-231 lower panels). In MDA-MB-231 derived cell lines, stable silencing of NURR1 resulted in decreased contralateral metastases
(arrow). B) Quantification of the tumor associated fluorescence was quantified, and NURR1 silencing resulted in significant (*two-way analysis of
variance, p < 0.01) inhibition in tumor growth by 35 days post inoculation in both cell lines).
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this point, NURR1 mislocalization to the cytoplasm is
associated with poor clinical prognosis, yet pharmaco-
logical modulation of the transcriptional function of
NURR1 is associated with compounds which induce
apoptosis [10,19]. Together, these findings suggest that
nuclear localization, and presumably transcriptional ac-
tivity of NURR1 is associated with differentiation,
whereas a cytosolic localization and a lack of transcrip-
tional activation are supportive of tumorigenesis. Indeed,
our own immunohistochemical studies suggest that in
normal cells, NURR1 is strongly localized to the nuclear
compartment, supporting the contention that NURR1
has differential roles in the normal and transformed
breast. Therefore, expression of the receptor alone may
not be indicative of its role in cancer, but its transcrip-
tional activity may be the key to elucidating its role in
the inhibition or promotion of breast cancer. Further
elucidation of this potential mechanism is complicatedby the fact that breast cancer cell lines are often intoler-
ant of NURR1 overexpression (data not shown). There-
fore, functional studies involving the transfection of
wild-type and transcriptionally inactive variants of
NURR1 will likely require a more nuanced approach,
such as conditional overexpression models.
NURR1 and breast cancer
In our studies, we have found that NURR1 silencing is
associated with increased incidence of lymph node me-
tastasis, and is associated with decreased expression of
the tumor suppressor p53. Strikingly, no NURR1(+) tu-
mors were associated with lymph node metastases,
which supports the notion that NURR1 functions as a
tumor suppressor. The prognostic significance of the in-
verse relationship between NURR1 and p53 expression
is unclear, but may yield some insight into the potential
mechanistic role of NURR1 in prevention of cancer de-
velopment. One intriguing possibility is that NURR1
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preventing entry into the cell cycle in the absence of p53
expression. A complicating factor however, is that p53 is
frequently mutated in cancer, thereby making it difficult
to assert whether p53 is active when it is expressed in
breast cancer [18].
Based on the findings in tissue arrays, it might be
expected that experimental silencing of NURR1 would re-
sult in an increase in tumor development and growth. To
the contrary, our observation that NURR1 silencing
caused a decrease in tumor growth in two xenograft
models suggests that NURR1 acquires a tumor promoting
function when expressed in transformed cells. It therefore
is unlikely that the tumor promoting effect of NURR1 is a
passive effect of inactive NURR1. Instead, we contend that
NURR1 actively contributes to oncogenic signaling under
currently undefined cellular conditions that could include
posttranslational modification of NURR1, protein-protein
interactions, or differential transactivation function of
NURR1. Interestingly, mRNAs encoding splice variants of
NURR1 have been characterized, and several of these pre-
sumed gene products have dominant negative effects with
regard to NURR1 –dependent transcriptional activity
[31,32]. As mentioned above, our early attempts to transi-
ently overexpress NURR1 in breast cancer suggest that
breast cancer cells are intolerant to NUR1 expression,
resulted in rapid cell death (data not shown). If taken into
context with these findings, this suggests that there may
be some threshold or “gene-dose” effect of NURR1 on
proliferation/survival in cancer, where low NURR1 expres-
sion levels may support proliferation, but higher levels of
expression may lead to cell cycle arrest or cell death
through distinct mechanisms
Conclusions
From these studies, we conclude that NURR1 expression
and transactivation is an integral component of normal
breast epithelial differentiation and functions as an indica-
tor for the efficacy of systemic therapy in breast cancer.
Additionally, we conclude that NURR1 acquires tumor
promoting effects within the context of the cancerous
breast, in which tolerable, low, significant levels of NURR1
expression support breast tumor development.
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